- Home
- APRE vs NDRA Comparison
APRE vs NDRA Comparison
Compare APRE & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- NDRA
- Stock Information
- Founded
- APRE 2006
- NDRA 2007
- Country
- APRE United States
- NDRA United States
- Employees
- APRE N/A
- NDRA N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- APRE Health Care
- NDRA Health Care
- Exchange
- APRE Nasdaq
- NDRA Nasdaq
- Market Cap
- APRE 6.9M
- NDRA 7.3M
- IPO Year
- APRE 2019
- NDRA 2017
- Fundamental
- Price
- APRE $1.16
- NDRA $4.53
- Analyst Decision
- APRE Strong Buy
- NDRA Strong Buy
- Analyst Count
- APRE 1
- NDRA 1
- Target Price
- APRE $20.00
- NDRA $38.00
- AVG Volume (30 Days)
- APRE 84.3K
- NDRA 45.9K
- Earning Date
- APRE 11-12-2025
- NDRA 11-17-2025
- Dividend Yield
- APRE N/A
- NDRA N/A
- EPS Growth
- APRE N/A
- NDRA N/A
- EPS
- APRE N/A
- NDRA N/A
- Revenue
- APRE $488,239.00
- NDRA N/A
- Revenue This Year
- APRE N/A
- NDRA N/A
- Revenue Next Year
- APRE N/A
- NDRA N/A
- P/E Ratio
- APRE N/A
- NDRA N/A
- Revenue Growth
- APRE N/A
- NDRA N/A
- 52 Week Low
- APRE $1.08
- NDRA $2.90
- 52 Week High
- APRE $5.00
- NDRA $11.96
- Technical
- Relative Strength Index (RSI)
- APRE 37.51
- NDRA 42.26
- Support Level
- APRE $1.08
- NDRA $6.06
- Resistance Level
- APRE $1.28
- NDRA $6.80
- Average True Range (ATR)
- APRE 0.09
- NDRA 0.84
- MACD
- APRE -0.01
- NDRA -0.12
- Stochastic Oscillator
- APRE 30.53
- NDRA 23.44
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.